Xeris Biopharma Holdings (XERS) Gains from Investment Securities (2020 - 2021)
Xeris Biopharma Holdings' (XERS) quarterly Gains from Investment Securities came in at $793000.0 in Q4 2021, up 1541.82% on a YoY basis from $48300.1 in Q4 2020, and up 1079.01% quarter-over-quarter from -$81000.0 in Q3 2021.
Powered by 
Analysis
Xeris Biopharma Holdings (XERS) Gains from Investment Securities (2020 - 2021) Analysis & Trends
Xeris Biopharma Holdings (XERS) has reported Gains from Investment Securities for 2 consecutive years, with $793000.0 the latest figure, recorded in Q4 2021.
- For the quarter ending Q4 2021, Gains from Investment Securities rose 1541.82% year-over-year to $793000.0; the trailing twelve-month figure through Dec 2021 stood at $817000.0 (changed N/A YoY), and the FY2021 full-year result was $702000.0, up 7700.0% from the prior year.
- Gains from Investment Securities advanced to $793000.0 in Q4 2021 per XERS's latest filing, from -$81000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $793000.0 in Q4 2021 and bottomed at -$81000.0 in Q3 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.48 Bn | 625.73 Bn | 17.26 Bn |
| 2 | AbbVie | 442.74 Bn | 436.17 Bn | 12.70 Bn |
| 3 | Merck | 366.39 Bn | 359.25 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.55 Bn | 258.86 Bn | 11.24 Bn |
| 5 | Pfizer | 158.80 Bn | 147.10 Bn | 10.94 Bn |
| 6 | Sanofi | 52.34 Bn | 44.96 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 8 | Incyte | 25.42 Bn | 20.88 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.53 Bn | 18.87 Bn | 683.80 Mn |
| 10 | Xeris Biopharma Holdings | 1.34 Bn | 1.22 Bn | 79.59 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | 793,000.00 |
| Sep 30, 2021 | -81,000.00 |
| Dec 31, 2020 | -55,000.00 |
| Sep 30, 2020 | 160,000.00 |